Overview
- The JAMA study published Thursday, Oct. 15, estimated that about 25.7% of active-duty male Army personnel — roughly 100,691 men — would have a morning total testosterone below the commonly used 300 ng/dL threshold.
- The Defense Health Agency has issued guidance requiring two separate early-morning tests and offers treatment options such as injections, gels, or oral drugs but does not mandate therapy.
- Researchers and clinical societies caution that a single low morning value does not diagnose hypogonadism and that most guidelines call for symptoms plus repeat testing before starting long-term therapy.
- Doctors and former military medical leaders warn that widespread screening could create large numbers of repeat tests and clinic visits, raise risks such as infertility and blood clots for some who start replacement therapy, and strain continuity of care during deployments.
- The rollout has been uneven and politically visible, with initial guidance posted, withdrawn, and reissued for men while guidance for women remains pending, leaving open questions about confidentiality, job fitness rules, and long-term VA coverage for treated service members.